22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023
07 August 2023 - 10:00PM
22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology
company dedicated to improving health with reduced nicotine
tobacco, hemp/cannabis and hops advanced plant technologies, will
host a live webcast on Monday, August 14, 2023, at 10:00 AM ET to
discuss its 2023 first quarter results, which are to be reported in
a press release at 6:00 AM ET the same day.
During the webcast, John Miller, interim chief executive
officer, and Hugh Kinsman, chief financial officer, will review
financial results and discuss progress made in each of the
Company’s three franchises.
Following management’s prepared remarks and slide presentation,
the Company will host a Q&A session, during which management
will accept questions from research analysts.
The live and archived webcast and slide presentation will be
accessible on the Events web page in the Company's Investor
Relations section of the website, at
https://ir.xxiicentury.com/events-and-presentations. Please access
the website at least 15 minutes prior to the start of the webcast
to register and, if necessary, download and install any required
software.
About 22nd Century Group,
Inc.22nd Century Group, Inc. (Nasdaq: XXII) is a
leading biotechnology company focused on utilizing advanced
alkaloid plant technologies to improve health and wellness through
tobacco harm reduction, reduced nicotine tobacco, hemp/cannabis and
hops. With dozens of patents allowing it to control nicotine
biosynthesis in the tobacco plant, the Company has developed
proprietary reduced nicotine content (RNC) tobacco plants and
cigarettes, which have become the cornerstone of the FDA’s
Comprehensive Plan to address the widespread death and disease
caused by smoking. The Company received the first and only FDA
Modified Risk Tobacco Product (MRTP) authorization of a combustible
cigarette in December 2021. In tobacco, hemp/cannabis and hop
plants, 22nd Century uses modern plant breeding technologies,
including genetic engineering, gene-editing, and molecular breeding
to deliver solutions for the life science and consumer products
industries by creating new, proprietary plants with optimized
alkaloid and flavonoid profiles as well as improved yields and
valuable agronomic traits.
Learn more at xxiicentury.com, on Twitter,
on LinkedIn, and on YouTube.
Learn more about
VLN® at tryvln.com.
Cautionary Note Regarding Forward-Looking
StatementsExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Forward-looking statements
typically contain terms such as “anticipate,” “believe,”
“consider,” “continue,” “could,” “estimate,” “expect,” “explore,”
“foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,”
“potential,” “predict,” “preliminary,” “probable,” “project,”
“promising,” “seek,” “should,” “will,” “would,” and similar
expressions. Actual results might differ materially from those
explicit or implicit in forward-looking statements. Important
factors that could cause actual results to differ materially are
set forth in “Risk Factors” in the Company’s Annual Report on Form
10-K filed on March 9, 2023. All information provided in this
release is as of the date hereof, and the Company assumes no
obligation to and does not intend to update these forward-looking
statements, except as required by law.
Investor Relations & Media ContactMatt
KrepsInvestor Relations22nd Century
Groupmkreps@xxiicentury.com214-597-8200
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From Apr 2024 to May 2024
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From May 2023 to May 2024